Biovica receives license for Maryland state

2023-12-01 08:00

Biovica, active in cancer diagnostics, today announces that the company has received a license for Maryland state, the 18th largest state in the US. The license means that Biovica can now perform analysis and report patient samples from all US states, except for New York and Washington DC.

"Our reach in the United States is steadily growing. We are now equipped to receive, test and report patient test results in 49 states, encompassing 94% or 311 million U.S. residents. Our latest state license enables us to partner with prominent medical facilities in Maryland, offering DiviTum TKa to oncologists for monitoring metastatic breast cancer in patients," says Warren Cresswell, President of Biovica Americas.

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No